title: IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
abstract: The level of interleukin-10 (IL-10) expression is related to polymorphisms -1082 (G/A), -819 (T/C) and -592 (A/C) in the promoter region of the IL-10 gene, which constitute three haplotypes, GCC, ATA, and ACC. The ATA (a non-GCC) haplotype, which is associated with low IL-10 expression, has been shown to improve interferon (IFN) treatment response in hepatitis C. We analysed the distribution of IL-10 promoter haplotype combinations to determine whether they could influence initial IFN treatment response in 63 patients with relapsing-remitting multiple sclerosis (MS). The patients were grouped into non-GCC or GCC haplotypes, and the clinical and magnetic resonance imaging (MRI) disease activity was compared in the two groups. During the first 6 months of treatment, MS patients with non-GCC haplotypes experienced fewer new MRI T1-contrast enhancing lesions [0.77+/-0.36 (SEM)] than patients with the GCC haplotype (2.45+/-0.57) (P=0.05, Mann-Whitney U test). No differences were detected on clinical disease activity. The results suggest an influence of IL-10 promoter polymorphisms on IFN treatment response in MS.
authors.affiliation: The Multiple Sclerosis National Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
authors.forename: S
authors.initials: S
authors.lastname: Wergeland
authors.forename: A
authors.initials: A
authors.lastname: Beiske
authors.forename: H
authors.initials: H
authors.lastname: Nyland
authors.forename: H
authors.initials: H
authors.lastname: Hovdal
authors.forename: D
authors.initials: D
authors.lastname: Jensen
authors.forename: J P
authors.initials: JP
authors.lastname: Larsen
authors.forename: T H
authors.initials: TH
authors.lastname: Marøy
authors.forename: A-I
authors.initials: AI
authors.lastname: Smievoll
authors.forename: C A
authors.initials: CA
authors.lastname: Vedeler
authors.forename: K-M
authors.initials: KM
authors.lastname: Myhr
mesh_terms: D000328:Adult; D001483:Base Sequence / Q000235:genetics; D002490:Central Nervous System / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D004252:DNA Mutational Analysis; D018450:Disease Progression; D004351:Drug Resistance / Q000235:genetics* / Q000276:immunology; D005260:Female; D005820:Genetic Testing; D006239:Haplotypes / Q000235:genetics*; D006801:Humans; D007372:Interferons / Q000494:pharmacology* / Q000627:therapeutic use; D016753:Interleukin-10 / Q000235:genetics* / Q000276:immunology; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D009413:Nerve Fibers, Myelinated / Q000276:immunology / Q000473:pathology; D011110:Polymorphism, Genetic / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics
chemical_list: D016753:Interleukin-10; D007372:Interferons